The National Institutes of Health’s National Cancer Institute (NCI) has awarded a grant for up to $3 million to NuvOx Pharma to initiate a Phase II clinical trial for the investigational drug, DDFPe, in the brain cancer, glioblastoma multiforme (GBM).
Search
Recent Posts
See AllTucson, AZ, October 12, 2021 --(PR.com)-- NuvOx Pharma, a Tucson based biotechnology company, has received a $478,000 NIH Phase I Small Business Technology Transfer (STTR) grant from the National Inst
Tucson, AZ, September 09, 2021 --(PR.com)-- NuvOx Pharma, a biotechnology company based in Tucson, Arizona, has generated positive preclinical data showing that its lead drug, NanO2TM, boosts the effi
Tucson, AZ, July 29, 2021 --(PR.com)-- NuvOx Pharma, a Tucson-based biopharmaceutical company, has received notice from the FDA that they may proceed with a Phase II clinical trial of their drug, NanO